Prostate Cancer
Our group is concerned with the identification of markers for
therapeutic responsiveness, prognostic markers, and new markers of
early prostate disease. We take a multidisciplinary approach that
utilises expertise from a number of cancer researchers within and
outside the Garvan, as well as clinicians and pathologists. Our
research aims to identify genes and pathways whose expression changes
can predict the development of aggressive life-threatening prostate
cancer or resistance to chemotherapy used for the treatment of advanced
stage prostate cancer.
Staff
Dr Maret Boehm |
Senior Research Officer Dr Lisa Horvath |
Dr Jack Zhao |
Brian Lee |
Warwick Locke |
Ainslee Mitchell |
Ruth Pe Benito |
Anne-Maree Haynes |
| Research Assistant Alice Boulghourjian |
PhD Student Paul Chen |
| Student Sarah Sutherland |
Data Clerks Sara Bassin Claire Lawley Li Yi Lim Ben Moore Amanda Siriwardana Sarah Zardawi |
| Visiting Scientists Dr Ruban Thanigasalam Associate Professor John Grygiel Dr Krishan Rasiah Associate Professor James Kench Professor Soon Lee Associate Professor Phil Stricker |
News
Garvan and St Vincent’s to Build $100 million Australian Cancer Centre
MEDIA RELEASE:
22 Oct 2008
The Garvan Institute of Medical Research and St Vincents & Mater Health Sydney will today announce plans to jointly establish a new $100 million Cancer Centre within the St Vincent’s Research Precinct. The Garvan St Vincent’s Campus Cancer Centre (GSVCCC) will integrate internationally acclaimed cancer research with best practice cancer services, enabling research findings to move quickly into patient care.
New prostate cancer marker helps identify men whose cancer is likely to spread
05 Oct 2006
Prostate cancer researchers at Sydney’s Garvan Institute found a new marker for identifying aggressive prostate cancers.
